Key facts
- It has raised $17.1M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Guangdong Technology Financial Group, Goldport Capital, Fuho Capital, HitGen, Longmen Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CrystalO Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for CrystalO Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CrystalO Biopharma
Manufacturer of membrane protein drugs intended for neuropsychiatric disorders, chronic kidney disease and cardiovascular disease. The company specailises in ion channel activity testing platforms, AI-based drug discovery tools, structure-guided compound design systems, preclinical validation models and molecular screening technologies, thereby improving therapeutic precision, accelerating drug development, and enhancing patient outcomes through technological innovation.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2019
- Website
- crystalobio.com/
- Ownership
- Privately Held (backing)
CrystalO Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CrystalO Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CrystalO Biopharma in its N-PORT filings yet. We sweep new filings monthly.